Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats
Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.
Eli Lilly and Company will build a $4.5 billion center for advanced manufacturing and drug development in Indiana to innovate new production methods.
Tirzepatide, an obesity drug of Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.